Connect Biopharma to Report First Half 2022 Financial Results on September 13

Rhea-AI Summary

Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced it will report financial results for the six months ending June 30, 2022, on September 13, 2022, after market close. The company will host a webcast and conference call at 1:30 p.m. PDT to discuss these results along with a corporate update. Connect Biopharma focuses on developing therapeutics for T cell-driven inflammatory diseases, with key candidates including CBP-201 for atopic dermatitis and asthma, and CBP-307 for ulcerative colitis.

Positive

• Company developing multiple therapeutic candidates targeting serious inflammatory diseases.
• Lead product candidate CBP-201 targets IL-4Rα for atopic dermatitis and asthma.
• Second candidate CBP-307 in development for ulcerative colitis.

Negative

• None.

Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT

SAN DIEGO and TAICANG, SUZHOU, China, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a company developing therapeutics for T cell-driven inflammatory diseases, today announced it will report financial results for the six-month period ended June 30, 2022, on Tuesday, September 13, after market close. Following the press release, the Company will host a webcast and conference call at 1:30 p.m. PDT to discuss the financial results and provide a corporate update.

The news release will be posted to the investor relations section of Connect Biopharma’s website at: https://investors.connectbiopharm.com/investors.

• To listen to the live webcast of the conference call, or the replay, which will be available for 12 months, investors can follow this link: https://edge.media-server.com/mmc/p/vftshcme.
• To participate in the live telephone conference call, follow this link to register in advance: Registration Link for Teleconference Dial In. Upon registering, you will receive a dial-in number and unique PIN to join the conference call.

About Connect Biopharma Holdings Limited
Connect Biopharma is a U.S. and China-based clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell research. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma. The Company’s second most advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, for the treatment of pruritus associated with AD. For more information, please visit: https://www.connectbiopharm.com/.

FAQ

When will Connect Biopharma report its financial results?

Connect Biopharma will report its financial results for the six months ended June 30, 2022, on September 13, 2022.

What is Connect Biopharma's lead product candidate?

The lead product candidate of Connect Biopharma is CBP-201, which targets interleukin-4 receptor alpha for treating atopic dermatitis and asthma.

Where can I find the webcast for Connect Biopharma's financial results?

The webcast for Connect Biopharma's financial results can be accessed via their investor relations website following the press release on September 13, 2022.

What diseases is Connect Biopharma targeting with its products?

Connect Biopharma is targeting various inflammatory diseases, including atopic dermatitis, asthma, and ulcerative colitis.